<?xml version="1.0" encoding="UTF-8"?>
<p>Numerous retrospective studies have indicated that prevalent clinical manifestations of COVID-19 patients are fever, dry cough and dyspnea [
 <xref rid="B4" ref-type="bibr">4</xref>]; less common symptoms present as the production of sputum, headache and some gastrointestinal symptoms; moreover, an increasing number of patients with asymptomatic infection patients have been discovered [
 <xref rid="B5" ref-type="bibr">5–7</xref>]. According to the latest guidelines of the diagnosis and treatment of pneumonitis caused by 2019-nCoV (trial version 7) published by the National Health Commission of the People’s Republic of China [
 <xref rid="B8" ref-type="bibr">8</xref>], the diagnosis of COVID-19 must be confirmed by reverse transcriptase-PCR (RT-PCR) or gene sequencing. At present, various biological samples of COVID-19 are used in the detection of SARS-CoV-2, and upper respiratory tract nasopharyngeal swabs are the most common sample type. However, growing evidence has revealed positive detection of nucleic acids in anal swabs of patients with COVID-19, although the positive rate is low [
 <xref rid="B9" ref-type="bibr">9</xref>,
 <xref rid="B10" ref-type="bibr">10</xref>].
</p>
